Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.
- None.
- None.
Insights
The comprehensive report by Veradigm Inc. on cardiovascular disease (CVD) prevalence in the United States presents significant findings that can influence healthcare strategies and patient management. The utilization of Natural Language Processing (NLP) to extract left ventricle ejection fraction (LVEF) data from unstructured clinical notes is particularly noteworthy. This approach has identified a substantial number of patients with potential heart failure and low LVEF who might have been overlooked using traditional data collection methods.
From a research perspective, the ability to acquire and analyze such large-scale, de-identified patient data enhances the understanding of disease patterns and risk factors. This can lead to more targeted and effective treatment protocols, potentially reducing the overall burden of CVD. Furthermore, the correlation of cardiovascular conditions with demographics and body mass index (BMI) categories offers valuable insights into the social determinants of health and could guide public health interventions aimed at reducing CVD risk factors in specific populations.
The Veradigm report's implications extend to economic considerations surrounding CVD management. The South's higher rates of hypertension, coronary artery disease and heart failure suggest a regional disparity in health outcomes that could translate into increased healthcare costs and resource allocation needs. By identifying these geographic and demographic disparities, policymakers and healthcare providers can better allocate resources to high-risk areas.
Furthermore, the association of CVD with BMI suggests that prevention efforts targeting obesity could have a significant impact on reducing CVD incidence and related healthcare expenses. The economic burden of CVD, which includes direct costs such as hospital care and indirect costs like lost productivity, could be mitigated through data-driven prevention and management strategies informed by reports like this one.
The insights provided by Veradigm's report have potential market implications for pharmaceutical companies, medical device manufacturers and healthcare service providers. Companies operating in the cardiovascular space can leverage this data to identify market needs and tailor their product development and marketing strategies accordingly. For instance, areas with higher prevalence rates may present opportunities for targeted therapies and patient education programs.
In addition, the use of advanced data analytics techniques such as NLP is indicative of a growing trend in healthcare towards more sophisticated data utilization. This could signal investment opportunities in healthcare technology firms specializing in data analysis and real-world evidence generation. Overall, the report underscores the importance of data-driven decision-making in the healthcare industry and its potential to influence market dynamics.
Using de-identified data for 53 million unique cardiovascular patients, the report examines prevalence across all 50 states and a variety of demographics
Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code. Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
Findings in this report are derived from the Veradigm Network EHR database, which connects over 400,000 healthcare providers and 200 million patients. It incorporates structured and unstructured data using Natural Language Processing (NLP) on approximately 100,000
“Veradigm is using NLP to extract typically inaccessible unstructured and semi-structured data. This has been quite impactful for left ventricle ejection fraction (LVEF),” said Machaon Bonafede, Vice President of Real-World Evidence at Veradigm. “NLP on unstructured clinical notes provides LVEF data on approximately 200,000 additional patients compared to what we can find in structured fields alone. This type of insight can help improve management of patients with cardiovascular disease and add clinical depth to our research.”
In the report, LVEF data pulled from unstructured clinical notes revealed almost 20,000 patients with possible heart failure and almost 30,000 with low function in the dataset. This type of previously inaccessible insight can help improve management of patients with cardiovascular disease and offers implications for early intervention.
“Cardiovascular disease is the leading cause of death across most segments of the population – men, women, and people of most racial and ethnic groups – in the U.S.,” said Stuart Green, Veradigm’s Senior Vice President and General Manager of Life Sciences. “Findings from Veradigm’s repository of de-identified data provides a larger story about the state of cardiovascular disease in
The data in this report were selected and mapped for states and 3-digit zip codes for a subset of 53 million patients in the Veradigm Network EHR database with evidence of cardiovascular risk factors or conditions. Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.
To download the report and learn more about the research, please visit: Veradigm Insights Report: Cardiovascular Conditions in 2024.
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.
© 2024 Veradigm Inc. and/or its affiliates. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220938851/en/
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com
Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@veradigm.com
Source: Veradigm
FAQ
Which company released the Veradigm Insights Report: Cardiovascular Conditions in 2024?
How many unique cardiovascular patients were included in the analysis?
What region of the U.S. has the highest rates of hypertension, coronary artery disease, and heart failure?
What type of data did Veradigm use for the report?
How many healthcare providers are connected through the Veradigm Network EHR database?
